<p>MS = Multiple Sclerosis; RRMS = relapsing-remitting MS; SPMS = secondary-progressive MS, CIS = clinically isolated syndrome; TL = tumefactive lesion; EL = enhancing lesion; DMT = disease modifying treatment; N/A = not applicable.</p
<p>Table 2 shows the demographics and clinical data of the patient cohort. These demographic and cli...
<p><b>Abbreviations:</b> MME = microcystic macular edema; MS = multiple sclerosis; NMO = neuromyelit...
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drug...
<p>F = female; LP = lumbar puncture time; EDSS = Expanded Disability Status Scale; ΔEDSS = differenc...
<p>Patients were excluded if they had other neurologic disease, a medical disease, had been undergoi...
<p><i>Abbreviations</i>: RR = Relapsing-remitting, SP = Secondary progressive, PP = Primary progress...
<p>DMT: disease-modifying therapy; PDDS: Patient Determined Disease Steps scale; RRMS: relapsing-rem...
<p><b>Abbreviations: ALS</b>: Amyotrophic Lateral Sclerosis, <b>BMT</b>: Bone marrow transplant, <b>...
OBJECTIVES: To assess the frequency of clinical features of Sjogren's syndrome (SS) in patients wi...
<p>*At least two-years of follow-up with the same disease modifying therapy (DMT) from a base line v...
<p>These patients had the classic characteristics of MS populations: F/M sex ratio 2.47 (19,656/7,94...
<p>Values for age, MS disease duration, EDSS and EDSS change are medians with interquartile ranges i...
<p>Note: - = no data; BPF = brain parenchymal fraction; EDSS = expanded disability status scale; F =...
<p>EDSS = Expanded Disability Status Scales; T2-LV = T2-hyperintense lesion volume; F = Females M = ...
<p>Data are expressed as median and range (in brackets). There were no statistically significant dif...
<p>Table 2 shows the demographics and clinical data of the patient cohort. These demographic and cli...
<p><b>Abbreviations:</b> MME = microcystic macular edema; MS = multiple sclerosis; NMO = neuromyelit...
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drug...
<p>F = female; LP = lumbar puncture time; EDSS = Expanded Disability Status Scale; ΔEDSS = differenc...
<p>Patients were excluded if they had other neurologic disease, a medical disease, had been undergoi...
<p><i>Abbreviations</i>: RR = Relapsing-remitting, SP = Secondary progressive, PP = Primary progress...
<p>DMT: disease-modifying therapy; PDDS: Patient Determined Disease Steps scale; RRMS: relapsing-rem...
<p><b>Abbreviations: ALS</b>: Amyotrophic Lateral Sclerosis, <b>BMT</b>: Bone marrow transplant, <b>...
OBJECTIVES: To assess the frequency of clinical features of Sjogren's syndrome (SS) in patients wi...
<p>*At least two-years of follow-up with the same disease modifying therapy (DMT) from a base line v...
<p>These patients had the classic characteristics of MS populations: F/M sex ratio 2.47 (19,656/7,94...
<p>Values for age, MS disease duration, EDSS and EDSS change are medians with interquartile ranges i...
<p>Note: - = no data; BPF = brain parenchymal fraction; EDSS = expanded disability status scale; F =...
<p>EDSS = Expanded Disability Status Scales; T2-LV = T2-hyperintense lesion volume; F = Females M = ...
<p>Data are expressed as median and range (in brackets). There were no statistically significant dif...
<p>Table 2 shows the demographics and clinical data of the patient cohort. These demographic and cli...
<p><b>Abbreviations:</b> MME = microcystic macular edema; MS = multiple sclerosis; NMO = neuromyelit...
The mechanisms leading to disability and the long-term efficacy and safety of disease modifying drug...